NFKB1 and neoplasm: In turn, NFKB1 -94 Del/Ins promoter polymorphisms presented significant differences with clinical stage (AOR: 0.218; 95% CI: 0.056∼0.985) (p<0.05) and tumor size (AOR: 0.200; 95% CI: 0.041∼0.981) (p<0.05) in female HCC patients with at least one NFKB1 -94 Ins polymorphism, while no associations were found in any male HCC patients.